EMA Authorised: Neofordex (dexamethasone) — THERAVIA

View source ↗

Summary

NEOFORDEX (dexamethasone) has been authorised for use in the European market by THERAVIA for multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Neofordex (dexamethasone)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: THERAVIA. Decision date: 25/08/2026